Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

Summary

Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal suppression and demonstrate increased bone turnover and consequent bone loss at the hip and spine. This bone loss can be prevented by treatment with 35 mg/week of risedronate.

Timeline

Start

2003-01

Primary completion

2008-03

Completion

2009-02

Outcome

Met primary endpoint

registry Risedronate 35 mg p.o. Every Week Plus Calcium and Vit D Daily vs Calcium and Vitamin D Daily (Placebo Group); p <0.01; ANOVA NCT00859027 ↗

Drugs

Indications